Max Lugavere on Controversial Alzheimer's Drugs and Studies
What this video covers
A widely shared clip from Lugavere’s first Joe Rogan Experience appearance (episode #1870, 2022), recorded in the wake of the Science magazine investigation that exposed fabricated data in influential Alzheimer’s research. In it, Lugavere walks Rogan through the amyloid hypothesis — sticky plaques as the disease’s causative force — and the 2006 Nature paper by University of Minnesota researcher Sylvain Lesné that identified an amyloid-beta subtype (Aβ*56) he claimed could rapidly impair a healthy mouse’s cognition. Lugavere says that paper renewed fervor in a hypothesis that was waning because drug trials kept failing — Alzheimer’s drug trials have a 99.6% failure rate, he claims — and that it ultimately led to the FDA’s controversial approval of the antibody drug aducanumab (Aduhelm).
He details the aducanumab case as he sees it: an 11-person FDA advisory panel in which eight members told the agency not to approve it; 35% of trial patients suffering brain swelling, half of those with associated bleeding; and no clinically meaningful improvement in cognition. Existing approved drugs, he says, are “biochemical band-aids” — minimally effective neurotransmitter modulators. He offers a striking analogy: expecting amyloid removal to restore cognition is “like thinking that if you remove all the headstones from a grave, people will come back to life,” since amyloid plaques also appear in the brains of healthy controls.
The clip’s other throughline is what Lugavere calls the “amyloid mafia”: he describes Vanderbilt researcher Matthew Schrag’s image-sleuthing on the post-publication peer-review site PubPeer, which exposed the fabricated western-blot data in Lesné’s paper, and recounts his own run-in — a nonprofit he describes as deeply invested in the amyloid hypothesis published a Wall Street Journal op-ed disparaging his documentary project (then titled Bread Head) while praising the drug before its approval. He closes by arguing for ketogenic interventions instead: in the Alzheimer’s brain, he claims, the ability to generate energy from glucose drops ~45–50% while the ability to use ketones is “unperturbed,” so a ketogenic diet could “keep the lights on.”
Key points
- Lugavere recounts the Lesné Aβ56 story: a 2006 Nature paper claiming a newly isolated amyloid-beta subtype impaired mouse cognition, reviving the amyloid hypothesis — until Matthew Schrag’s PubPeer image-sleuthing showed the western-blot data was fabricated and Aβ56 was never found by any other team. (The image-manipulation findings in Lesné’s papers are documented; Lugavere’s broader claim that this invalidates the field’s direction is his interpretation.)
- He presents the fabricated paper as what renewed fervor in the amyloid hypothesis and ultimately led to aducanumab’s approval — a causal chain presented as his argument, not an established fact.
- On aducanumab (Aduhelm), he cites specifics: 8 of 11 FDA advisory panel members voted against approval, 35% of trial patients had brain swelling (half of those with bleeding), and the drug showed no clinically meaningful cognitive benefit.
- He calls existing approved drugs “biochemical band-aids” that modulate neurotransmitters without addressing underlying disease, and notes amyloid plaques also appear in healthy brains with no correlation to cognition.
- He describes the “amyloid mafia” — researchers who, he says, ridiculed and silenced alternate viewpoints, and a nonprofit that published a Wall Street Journal op-ed disparaging his documentary while praising the drug pre-approval — and says the Department of Justice may investigate the fabrication.
- He argues the alternative is metabolic: because the Alzheimer’s brain loses ~45–50% of its ability to generate energy from glucose while ketone use stays “unperturbed,” he favors ketogenic interventions to “keep the lights on.”
- Rogan’s reaction on the clip helped the segment travel; it has been viewed nearly 700,000 times as a standalone clip.